###begin article-title 0
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
Polymorphisms of FCRL3 in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
The polymorphisms of the Fc receptor-like 3 gene (FCRL3), a novel immunoregulatory gene, have been shown to be associated with certain autoimmune diseases. This study was designed to examine whether the polymorphisms of FCRL3 are associated with susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Chinese population.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 177 182 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 312 319 312 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 325 334 325 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 282 287 <span type="species:ncbi:9606">human</span>
A case-control study was performed in 230 Chinese VKH patients and 301 healthy controls. Four single nucleotide polymorphisms (SNPs; -169C/T, -110A/G, +358C/G, and +1381A/G) in FCRL3 were detected using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). human leukocyte antigen -DR4 (HLA-DR4) and HLA-DRw53 genotyping was performed using PCR techniques.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 230 237 230 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 264 271 264 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 300 302 300 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 314 316 314 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 461 468 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 473 482 473 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 541 544 541 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;16</sup>
###xml 558 560 558 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 614 621 614 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 626 635 626 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 668 673 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 438 446 <span type="species:ncbi:9606">patients</span>
The results showed that the frequency of haplotype CACG was significantly lower in patients when compared with that in controls (p=0.0018, corrected p [pc]=0.0288). A significantly higher frequency was found for haplotype CGGG in HLA-DR4 negative patients than in HLA-DR4 negative controls (p=9.94x10-8, Pc=1.59x10-6). There were no significant differences in the allele and genotype frequencies of the four investigated SNPs between VKH patients and controls. HLA-DR4 and HLA-DRw53 were significantly associated with VKH syndrome (p=3.21x10-16 and p=7.08x10-5, respectively). Stratification analysis according to HLA-DR4 and HLA-DRw53 did not show any association of FCRL3 polymorphisms with VKH syndrome.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 59 68 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 284 291 284 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
Our study confirms the previous association of HLA-DR4 and HLA-DRw53 with VKH syndrome but fails to demonstrate an association between FCRL3 polymorphisms and VKH syndrome. Haplotype CACG might be a protective haplotype for VKH syndrome, and haplotype CGGG may be a risk haplotype in HLA-DR4 negative individuals.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 743 744 743 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 855 856 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 940 943 940 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 946 953 946 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 958 967 958 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 969 970 969 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 1044 1051 1044 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 1056 1065 1056 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1162 1165 1162 1165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;16</sup>
###xml 1179 1181 1179 1181 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;5</sup>
###xml 1198 1200 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 1257 1260 1257 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 1352 1355 1352 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 1443 1445 1443 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 783 789 <span type="species:ncbi:9606">people</span>
###xml 915 920 <span type="species:ncbi:9606">human</span>
###xml 1107 1115 <span type="species:ncbi:9606">patients</span>
Vogt-Koyanagi-Harada (VKH) syndrome is one of the most common uveitis entities in China [1]. The major clinical manifestations of VKH syndrome include panuveitis, pleocytosis in the cerebrospinal fluid, dysacusis, alopecia, poliosis, and vitiligo [2-4]. Although the pathogenesis of VKH syndrome remains uncertain, accumulating evidence suggests that both autoimmune and genetic factors are involved in the development of this disease. Previous research showed that VKH is a T-cell-mediated autoimmune disorder predominantly against melanocytes [5] and that the tyrosinase family proteins may play an important role in VKH disease. Lymphocytes of VKH patients were shown to proliferate in response to tyrosinase or tyrosinase related protein [6]. VKH occurs most commonly in colored people such as certain Asian, American-Indian, and Spanish populations [7], particularly in those carrying the genes coding for the human leukocyte antigen (HLA), HLA-DR4 and HLA-DRw53 [8-10]. A study in our laboratory recently reported that the frequencies of HLA-DR4 and HLA-DRw53 were both significantly increased in VKH patients (odds ratios [OR]=13.74 and OR=4.13, p=3.21x10-16 and p=7.08x10-5, respectively) [11]. However, the association between VKH syndrome and the HLA system does not completely explain the genetic risk for this disease. Investigation of non-HLA susceptibility genes for VKH has been an ongoing research subject during recent years [12].
###end p 11
###begin p 12
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL</italic>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRH</italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL</italic>
###xml 242 249 242 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fc&#947;</italic>
###xml 266 274 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fc&#947;R</italic>
###xml 337 342 329 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL1</italic>
###xml 343 348 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCLR6</italic>
###xml 387 389 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 392 397 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 531 533 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 536 541 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 756 758 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 788 793 780 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 898 900 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 921 923 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 961 963 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 964 966 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 998 1000 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 1001 1003 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 1234 1239 1226 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 1302 1307 1294 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 139 144 <span type="species:ncbi:9606">human</span>
Fc receptor-like genes (FCRLs), also known as FCRHs (Fc receptor homology), cluster in the midst of the classical Fc receptor genes in the human chromosome 1q21-23 region [13]. FCRLs with similarity in structure and sequence to the classical Fcgamma receptor genes (FcgammaR) contain six immunoglobulin (Ig) superfamily members known as FCRL1-FCLR6 according to their chromosomal order [14]. FCRL3 is predominantly expressed in lymphoid organs, more precisely in germinal centers, and has been linked to the maturation of B cells [15]. FCRL3 may play a role in the differentiation of B cells into autoreactive cells and has been presumed to function through modulating signal transduction via activation/inactivation of signaling tyrosine protein kinases [16]. Recently, polymorphisms of FCRL3 have been reported to be associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) [17], Behcet's disease [18], autoimmune thyroid disease (AITD) [17,19], and multiple sclerosis (MS) [20,21]. The first two have a strong autoantibody component whereas the latter three are predominately mediated by T-cell response. As an autoimmune disease, VKH may share a common pathogenesis with these autoimmune diseases. Therefore, FCRL3 was chosen as a target gene for VKH syndrome. Whether SNPs of FCRL3 are also associated with the susceptibility to VKH syndrome is not yet known, and this question was therefore the subject of the study described here.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants
###end title 14
###begin p 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
Patients and controls consisted of 230 Chinese VKH patients and 301 healthy controls. All control subjects were matched ethnically and geographically with the patients. The test subjects were recruited from the Zhongshan Ophthalmic Center of Sun Yat-sen University (Guangzhou, China) and the First Affiliated Hospital of Chongqing Medical University (Chongqing, China). To exclude the immunogenetic backgrounds of different populations, we strictly chose the cases from Chinese Han descendents.
###end p 15
###begin p 16
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 145 152 145 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
The diagnosis of VKH syndrome followed the revised criteria for this disease [22]. The clinical characteristics of the patients are presented in Table 1. All subjects gave their written informed consent for this study, and the study protocol was approved by the local institutional ethics committee.
###end p 16
###begin title 17
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 12 21 12 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
HLA-DR4 and HLA-DRw53 distribution and clinical characteristics of 230 patients with VKH syndrome.
###end title 17
###begin title 18
Single nucleotide polymorphisms and genotyping
###end title 18
###begin p 19
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Genomic DNA samples of VKH patients and healthy controls were extracted and isolated from ethylene diamine tetraacetic acid (EDTA)-anticoagulated peripheral blood mononuclear cells (PBMCs) by a conventional salting out method and stored at -70 degreesC until use.
###end p 19
###begin p 20
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 561 568 561 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
The four single nucleotide polymorphisms (SNPs) in FCRL3, -169C/T ( or fcrl3_3), -110G/A ( or fcrl3_4), +358C/G ( or fcrl3_5), and +1381A/G ( or fcrl3_6), were genotyped by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Genotyping of the -110G/A SNP was performed according to the method described previously [23]. The primers of the three remaining loci were designed using premier 5.0 software (Premier Biosoft International, Palo Alto, CA). The details of the primers and enzymes used for PCR-RFLP genotyping are presented in Table 2.
###end p 20
###begin title 21
Details of the primers, enzymes, and temperature used in PCR-RFLP genotyping.
###end title 21
###begin p 22
###xml 557 564 543 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 644 646 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 649 658 635 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 705 707 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
PCR was performed in 15 mul volumes containing 7.5 mul Premix Taq (Ex Taq Version; TaKaRa Biotechnology Co. Ltd., Dalian, China), 0.5 mul primers (10 mumol/l), and 0.1 mug of genomic DNA. The PCR products were then digested by the proper restriction enzymes, separated by electrophoresis on 2%-3% agarose gel, and stained with GoldViewtrade mark (SBS Genetech, Beijing, China). The images were recorded digitally. Approximately 20% of the PCR samples were directly sequenced to confirm the PCR-RFLP results (Invitrogen Biotechnology Co., Guangzhou, China). HLA-DR4 genotyping was performed using the PCR sequence specific primers (SSP) method [24]. HLA-DRw53 typing was performed as described previously [25].
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 158 159 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 245 246 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 419 421 415 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 422 424 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
Statistical analysis was performed with the SPSS version 12.0 for Windows (SPSS Inc., Chicago, IL). The Hardy-Weinberg equilibrium (HWE) was tested by the chi2 test. We evaluated the frequency of alleles and genotypes in this study using the chi2 test or Fisher's exact test and accounting for multiple testing. The haplotype frequency and linkage disequilibrium (LD) of the SNPs were estimated with the  3.32 program [26,27]. A haplotype frequency less than 0.03 was not analyzed. All the data were corrected by Bonferroni correction.
###end p 24
###begin title 25
Results
###end title 25
###begin p 26
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 162 165 <span type="species:ncbi:9606">men</span>
###xml 187 192 <span type="species:ncbi:9606">women</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
The test subjects consisted of 230 VKH patients (aged 33.4+/-12.6 years) and 301 healthy controls (aged 35.3+/-11.9 years). Of the 230 patients, 128 (55.7%) were men and 102 (44.3%) were women. No statistical difference was observed between patients and controls in the distribution of age and gender (p=0.43, p=0.82, respectively). All the cases and controls were in Hardy-Weinberg equilibrium (p>0.05). Therefore, we did the following analysis.
###end p 26
###begin p 27
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 200 205 200 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 353 360 353 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 618 619 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 626 633 624 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 556 564 <span type="species:ncbi:9606">patients</span>
Four SNPs (-169C/T, -110A/G, +358C/G, and +1381A/G) in FCRL3 were determined in all patients and controls. The results showed that a significantly higher frequency of the G allele at the -110 site of FCRL3 was observed in VKH patients than in controls (p=0.0129), but this significance was lost after the Bonferroni correction (corrected p [Pc]=0.1032; Table 3). No significant difference was observed in the distribution of other tested alleles or genotypes between VKH patients and controls. The frequency of haplotype CACG was signficantly lower in VKH patients (0.3%) than in controls(3.0%; p=0.0018,Pc=0.0288, chi2=9.77; Table 4).
###end p 27
###begin title 28
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Frequency of different alleles and genotypes in four FCRL3 SNPs in VKH patients and controls.
###end title 28
###begin p 29
Pc: Corrected p value; NS: Not significant; OR: odds ratios.
###end p 29
###begin title 30
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Frequencies of FCRL3 haplotypes in VKH patients and controls.
###end title 30
###begin p 31
The asterisk indicates that the frequency is less than 3% in both VKH cases and control.
###end p 31
###begin p 32
###xml 276 283 276 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
We further analyzed the relationship between these SNPs and various extraocular clinical findings including neck stiffness, tinnitus, alopecia, poliosis, dysacusia, scalp hypersensitivity, and vitiligo. The detailed clinical findings of the enrolled VKH patients are shown in Table 1. No significant difference was noted between any clinical parameter stated above and the investigated SNPs.
###end p 32
###begin p 33
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 12 21 12 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 162 169 162 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 174 183 174 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 281 284 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;16</sup>
###xml 318 321 318 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 408 415 408 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 420 429 420 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 509 516 509 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 539 546 539 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 591 593 591 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 605 607 605 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 609 616 609 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 526 534 <span type="species:ncbi:9606">patients</span>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
HLA-DR4 and HLA-DRw53 were also determined in VKH patients and controls using the PCR-SSP and PCR method [24,25]. The results showed that the frequencies of both HLA-DR4 and HLA-DRw53 were significantly higher in VKH patients than in healthy controls (77.4% versus 19.6%, p=7.34x10-16 and 87.8% versus 64.1%, p=5.59x10-10, respectively). Stratification analysis was then performed according to the status of HLA-DR4 and HLA-DRw53. A significant difference was found in the frequency of haplotype CGGG between HLA-DR4 negative patients and HLA-DR4 negative controls (5.8% versus 0%, p=9.94x10-8, Pc=1.59x10-6; Table 5). The results did not show any association of allele and genotype frequencies of the four SNPs between VKH patients and normal controls following these stratifications.
###end p 33
###begin title 34
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 35 42 35 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 69 76 69 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Frequencies of FCRL3 haplotypes in HLA-DR4 negative VKH patients and HLA-DR4 negative controls.
###end title 34
###begin p 35
The asterisk indicates that the frequency was less than 3% in both VKH case and control.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 312 319 312 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 389 396 389 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 401 410 401 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 507 512 507 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 628 633 628 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 826 831 822 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 876 884 <span type="species:ncbi:9606">patients</span>
###xml 902 910 <span type="species:ncbi:9606">patients</span>
We analyzed the association of the aforementioned four SNPs and haplotypes of FCRL3 in the susceptibility to VKH syndrome in a Chinese population. The results showed that the frequency of haplotype CACG was significantly lower in VKH patients and that the frequency of haplotype CGGG was significantly higher in HLA-DR4 negative VKH patients. The results also confirmed the association of HLA-DR4 and HLA-DRw53 with VKH syndrome as expected. Furthermore, previous studies showed strong associations between FCRL3 polymorphisms and RA in Asian groups but hardly in Caucasians [16] except a study in Spain [28], which showed that FCRL3 polymorphisms were associated with RA after stratification by nuclear factor kappa B1 (NF-kappaB1). VKH syndrome is quite common in both Asian and Spanish populations. The association between FCRL3 and VKH may be of importance in Chinese VKH patients and Hispanic VKH patients.
###end p 37
###begin p 38
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 9 17 <span type="species:ncbi:9606">patients</span>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 285 292 <span type="species:ncbi:9606">persons</span>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
The test patients were strictly enrolled as VKH syndrome patients according to the revised criteria [22]. As ethnic confounding could influence the results, we selected only Chinese Han descendents as the test subjects. Moreover, the healthy controls in this study were all limited to persons who came from the same places as the patients, which avoided a geographic bias.
###end p 38
###begin p 39
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 477 482 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 645 647 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 701 706 697 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
As a novel immunoregulatory gene, FCRL3 has been reported to be positively associated with various autoimmune diseases in different ethnic populations [17,19,21,29,30], though certain results were conflicting [28,31]. A study by Kochi et al. [17] in Japan found that the four SNPs of FCRL3 (-169C/T, -110A/G, +358C/G, and +1381A/G) were associated with RA and that SNP -169C/T was associated with AITD and SLE. Furthermore, -169C/T SNP has been shown to influence the level of FCRL3 expression on B cells by altering the binding affinity of NF-kappaB, which appears to play a major role in the inflammatory response according to recent studies [32]. Therefore, we speculated that polymorphisms within FCRL3 could also be related to VKH syndrome.
###end p 39
###begin p 40
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 481 486 481 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 1072 1077 1072 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 1151 1153 1151 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 1190 1192 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 1274 1279 1274 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
###xml 997 1005 <span type="species:ncbi:9606">patients</span>
Although no significant differences were found in the frequencies of the four investigated SNPs of FCRL3 between VKH patients and normal controls, an increase trend was observed in the frequency of the -110G allele in VKH patients. This result is similar to the study we recently reported in Behcet's disease in which only the FCRL3 -110G allele was significantly higher in BD patients and no differences were observed in the remaining three tested SNPs [18]. The polymorphisms of FCRL3 were reported to be associated with RA in Japan [17,30] and MS in Spain [20,21], but the associations could not be replicated completely in other autoimmune diseases [23,33]. In the study of Graves' disease [19], three of the four SNPs (except -110A/G SNP) were associated with this autoimmune thyroid disease. A study by Japanese investigators [34] also showed that only -110A/G SNP was associated with autoimmune pancreatitis, but contrary to our result, the frequency of -110G allele was decreased in these patients. Similar negative results were obtained for the same four SNPs of FCRL3 in other studies concerning type 1 autoimmune hepatitis in the Japanese [35] and SLE in the Chinese population [36]. These observations demonstrated that the relationship between polymorphisms of FCRL3 and autoimmune diseases is more complex than we thought, especially in some multiple autoimmune disorders.
###end p 40
###begin p 41
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 649 657 <span type="species:ncbi:9606">patients</span>
###xml 855 863 <span type="species:ncbi:9606">patients</span>
The further haplotype analysis showed that the frequency of haplotype CACG was significantly lower in VKH patients. This suggests that the haplotype CACG might be a protective haplotype for VKH syndrome. However, the frequency of this haplotype in patients and controls is very low (0.3% versus 3%), making it hard to make any firm conclusion on this significance. The present results were different from those found in BD [18] and SLE [37]. The study of BD in our laboratory found that haplotype CGCG and TACG were both associated with BD in which the first one was found to be significantly higher whereas the latter was significantly lower in BD patients as compared with healthy controls. While in the study of SLE in Spanish individuals, only three alleles were examined and the frequency of haplotype CGA was found to be significantly higher in SLE patients than in controls.
###end p 41
###begin p 42
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 296 303 296 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 308 317 308 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 460 467 460 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 472 482 472 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA- DRw53</italic>
###xml 532 539 532 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 544 553 544 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 647 648 647 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 787 794 787 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 799 808 799 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 950 957 950 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 984 991 984 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 1087 1094 1087 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 1179 1186 1179 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 1217 1224 1217 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 1420 1422 1420 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 1423 1425 1423 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 1428 1436 1428 1436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 1439 1442 1439 1442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DR1</italic>
###xml 1449 1452 1449 1452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DR4</italic>
###xml 1498 1500 1498 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 1640 1642 1640 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 1664 1666 1664 1666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 691 699 <span type="species:ncbi:9606">patients</span>
###xml 967 975 <span type="species:ncbi:9606">patients</span>
###xml 1200 1208 <span type="species:ncbi:9606">patients</span>
VKH occurs most commonly in pigmented individuals and not in whites, but interestingly, the disease is rare in Africans [7]. It seems that the genetic background in these individuals rather than the amount of pigment is the predisposing factor to VKH syndrome. Various studies have reported that HLA-DR4 and HLA-DRw53 were significantly associated with VKH syndrome [8-10]. We therefore analyzed the association of the four SNPs with VKH syndrome based on the HLA-DR4 and HLA- DRw53 stratification. We found that the association of HLA-DR4 and HLA-DRw53 with VKH syndrome was extremely strong, which is consistent with earlier studies from China [8,38], Japan [10], Korea [39], and Hispanic patients living in California [40]. However, stratification analysis according to the status of HLA-DR4 and HLA-DRw53 still showed that none of the four SNPs was associated to VKH syndrome. However, the frequency of haplotype CGGG was significantly higher in HLA-DR4 negative patients than in HLA-DR4 negative controls. Haplotype CGGG is probably a risk haplotype predisposing to VKH syndrome in HLA-DR4 negative subgroups. The samples become small after stratification, consisting of 52 HLA-DR4 negative VKH patients and 242 HLA-DR4 negative normal controls. The influence of insufficient sample size can not be excluded yet. Various studies showed that VKH shared epitopes with other autoimmune disease-associated HLA alleles [41-43]. HLA-DQB1, -DR1, and -DR4 all were susceptible genes for VKH syndrome [44], and importantly, these HLA antigens were also associated with the susceptibility to other autoimmune diseases including type 1 diabetes [45]and Graves' disease [46].
###end p 42
###begin p 43
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
Systemic disease is a prominent feature of VKH syndrome. There is a large variation in systemic clinical manifestations in Chinese VKH patients [4]. Stratification analysis was therefore performed to investigate the association between the polymorphisms of FCRL3 and clinical manifestations. The results showed that none of these clinical findings, which included neck stiffness, tinnitus, alopecia, poliosis, dysacusia, scalp hypersensitivity, and vitiligo, was significantly associated with the four SNPs. Similarly, no association was found after gender and age stratification.
###end p 43
###begin p 44
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 248 255 248 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 339 346 339 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 351 360 351 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 446 451 446 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FCRL3</italic>
###xml 488 495 <span type="species:ncbi:9606">patient</span>
In conclusion, no significant correlation could be observed between the FCRL3 polymorphisms and VKH syndrome in the Chinese population. Haplotype CACG might be a protective haplotype for VKH syndrome. Haplotype CGGG is probably a risk haplotype in HLA-DR4 negative individuals. Similar to previous studies, we found strong associations of HLA-DR4 and HLA-DRw53 with VKH syndrome. Further studies of these SNPs and including other variants in the FCRL3 region, using larger (multi-center) patient numbers, and including various autoimmune diseases should be performed in the future.
###end p 44
###begin title 45
Acknowledgments
###end title 45
###begin p 46
This study was supported by the Key Project of Natural Science Foundation (30630064), National Supporting Project of P.R. China (2007BAI18B10), Clinical Key Project of Ministry of Health of P.R China, and Key Project of Chongqing Health Bureau and National Basic Research Program of China (2007CB512200).
###end p 46
###begin title 47
References
###end title 47
###begin article-title 48
Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China.
###end article-title 48
###begin article-title 49
Vogt-Koyanagi-Harada syndrome.
###end article-title 49
###begin article-title 50
Echographic features of the Vogt-Koyanagi-Harada syndrome.
###end article-title 50
###begin article-title 51
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.
###end article-title 51
###begin article-title 52
Update on uveomeningoencephalitides.
###end article-title 52
###begin article-title 53
Pathogenesis of Vogt-Koyanagi-Harada disease.
###end article-title 53
###begin article-title 54
Vogt-Koyanagi-Harada disease.
###end article-title 54
###begin article-title 55
Association of HLA antigens with Vogt-Koyanagi-Harada syndrome in a Han Chinese population.
###end article-title 55
###begin article-title 56
###xml 10 15 <span type="species:ncbi:9606">human</span>
Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome.
###end article-title 56
###begin article-title 57
HLA class II genes in Vogt-Koyanagi-Harada disease.
###end article-title 57
###begin article-title 58
Small ubiquitin-like modifier 4 (SUMO4) polymorphisms and Vogt-Koyanagi-Harada (VKH) syndrome in the Chinese Han population.
###end article-title 58
###begin article-title 59
Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome.
###end article-title 59
###begin article-title 60
Identification of a family of Fc receptor homologs with preferential B cell expression.
###end article-title 60
###begin article-title 61
Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family.
###end article-title 61
###begin article-title 62
Fc receptor-like molecules.
###end article-title 62
###begin article-title 63
Is FCRL3 a new general autoimmunity gene?
###end article-title 63
###begin article-title 64
A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities.
###end article-title 64
###begin article-title 65
Association between polymorphisms of FCRL3, a non-HLA gene, and Behcet's disease in a Chinese population with ophthalmic manifestations.
###end article-title 65
###begin article-title 66
Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves' disease.
###end article-title 66
###begin article-title 67
The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis.
###end article-title 67
###begin article-title 68
FcRL3 and multiple sclerosis pathogenesis: role in autoimmunity?
###end article-title 68
###begin article-title 69
Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.
###end article-title 69
###begin article-title 70
Analysis of the Fc receptor-like-3 (FCRL3) locus in Caucasians with autoimmune disorders suggests a complex pattern of disease association.
###end article-title 70
###begin article-title 71
Identification of the HLA-DRB1*04, -DRB1*07, and -DRB1*09 alleles by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours.
###end article-title 71
###begin article-title 72
HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.
###end article-title 72
###begin article-title 73
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 73
###begin article-title 74
Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms.
###end article-title 74
###begin article-title 75
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Epistatic interaction between FCRL3 and NFkappaB1 genes in Spanish patients with rheumatoid arthritis.
###end article-title 75
###begin article-title 76
FCRL3 promoter 169 CC homozygosity is associated with susceptibility to rheumatoid arthritis in Dutch Caucasians.
###end article-title 76
###begin article-title 77
Supportive evidence for a genetic association of the FCRL3 promoter polymorphism with rheumatoid arthritis.
###end article-title 77
###begin article-title 78
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Meta-analysis evidence of a differential risk of the FCRL3 -169T-->C polymorphism in white and East Asian rheumatoid arthritis patients.
###end article-title 78
###begin article-title 79
NF-kappaB activation and inhibition: a review.
###end article-title 79
###begin article-title 80
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Epistatic interaction between FCRL3 and MHC in Spanish patients with IBD.
###end article-title 80
###begin article-title 81
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Genetic association of Fc receptor-like 3 polymorphisms with autoimmune pancreatitis in Japanese patients.
###end article-title 81
###begin article-title 82
Lack of association between FCRL3 and FcgammaRII polymorphisms in Japanese type 1 autoimmune hepatitis.
###end article-title 82
###begin article-title 83
Lack of association between Fc receptor-like 3 gene polymorphisms and systemic lupus erythematosus in Chinese population.
###end article-title 83
###begin article-title 84
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Polymorphisms of the FCRL3 gene in a Spanish population of systemic lupus erythematosus patients.
###end article-title 84
###begin article-title 85
The association of HLA-DR4 gene subtypes with Vogt-Koyanagi-Harada syndrome.
###end article-title 85
###begin article-title 86
Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans.
###end article-title 86
###begin article-title 87
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California.
###end article-title 87
###begin article-title 88
Crohn's disease in the Japanese is associated with the HLA-DRw53.
###end article-title 88
###begin article-title 89
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 143 151 <span type="species:ncbi:9606">children</span>
Polymorphism of human HLA-DRB1 leukocyte antigen alleles and its association to juvenile rheumatoid arthritis in a sample of Colombian mestizo children.
###end article-title 89
###begin article-title 90
The rheumatoid arthritis-associated allele HLA-DR10 (DRB1*1001) shares part of its repertoire with HLA-DR1 (DRB1*0101) and HLA-DR4 (DRB*0401).
###end article-title 90
###begin article-title 91
###xml 38 46 <span type="species:ncbi:9606">patients</span>
HLA-DRB1 and -DQB1 alleles in mestizo patients with Vogt-Koyanagi-Harada's disease in Southern California.
###end article-title 91
###begin article-title 92
Genetic markers for insulin-dependent diabetes mellitus in Japanese.
###end article-title 92
###begin article-title 93
###xml 41 46 <span type="species:ncbi:9606">human</span>
Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population.
###end article-title 93

